Your browser is no longer supported. Please, upgrade your browser.
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.41 Insider Own2.00% Shs Outstand45.79M Perf Week-12.37%
Market Cap663.20M Forward P/E- EPS next Y-1.99 Insider Trans-51.53% Shs Float44.67M Perf Month-8.54%
Income-200.80M PEG- EPS next Q-0.76 Inst Own- Short Float22.34% Perf Quarter-19.83%
Sales79.40M P/S8.35 EPS this Y21.30% Inst Trans-8.17% Short Ratio9.90 Perf Half Y-22.44%
Book/sh2.78 P/B5.05 EPS next Y44.00% ROA-50.90% Target Price- Perf Year-63.09%
Cash/sh5.60 P/C2.50 EPS next 5Y- ROE-121.80% 52W Range10.80 - 39.34 Perf YTD-41.95%
Dividend- P/FCF- EPS past 5Y-17.10% ROI-52.70% 52W High-64.34% Beta0.95
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin86.70% 52W Low29.91% ATR1.05
Employees380 Current Ratio4.30 Sales Q/Q86.20% Oper. Margin- RSI (14)43.41 Volatility7.05% 7.45%
OptionableYes Debt/Eq1.52 EPS Q/Q-1.30% Profit Margin- Rel Volume1.38 Prev Close14.22
ShortableYes LT Debt/Eq1.52 EarningsMay 06 AMC Payout- Avg Volume1.01M Price14.03
Recom1.90 SMA20-8.24% SMA50-2.31% SMA200-27.01% Volume1,393,831 Change-1.34%
May-07-20Reiterated H.C. Wainwright Buy $37 → $31
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-09-17Downgrade Raymond James Strong Buy → Mkt Perform
Mar-08-17Reiterated RBC Capital Mkts Outperform $54 → $55
Mar-08-17Reiterated Needham Buy $52 → $58
Feb-17-17Initiated ROTH Capital Buy $69
May-26-20 12:36AM  Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-11-20 07:15PM  Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)? Insider Monkey +5.04%
May-07-20 06:30PM  Aerie Pharmaceuticals Inc (AERI) Q1 2020 Earnings Call Transcript Motley Fool -7.79%
May-06-20 05:15PM  Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire
03:00PM  Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-05-20 07:30AM  Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference Business Wire
Apr-29-20 07:30AM  Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Business Wire +9.81%
Apr-28-20 12:34PM  Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy? Zacks -5.22%
Apr-13-20 10:01AM  Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak Zacks
Apr-09-20 04:01PM  Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19 Business Wire +13.81%
Apr-07-20 07:30AM  Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference Business Wire +5.92%
Apr-02-20 02:54PM  Gone: Triangle public companies lose $30 billion in value during 1Q 2020 American City Business Journals
Mar-25-20 10:18AM  Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap TipRanks
Mar-21-20 11:30AM  Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report? Zacks
Feb-27-20 07:23AM  Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -9.18%
05:19AM  Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-24-20 02:59PM  Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus American City Business Journals -5.97%
07:30AM  Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-21-20 11:30AM  Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat Zacks +8.55%
07:46AM  The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 05:35PM  Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Business Wire
10:50AM  Some Market Stats In 5 Minutes Benzinga
Feb-18-20 06:30AM  Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax Business Wire
Feb-13-20 07:30AM  Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020 Business Wire
Feb-12-20 05:13AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
Feb-03-20 06:30AM  Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs Business Wire
Jan-21-20 06:30AM  Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Business Wire
Jan-08-20 05:18PM  How Did Aerie Pharmaceuticals Inc (AERI) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 05:26AM  Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet? Simply Wall St.
Jan-03-20 10:04AM  Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks
Jan-02-20 08:46AM  The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
06:30AM  Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe Business Wire
Dec-09-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance Business Wire +5.91%
Dec-06-19 11:31AM  Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 09:19AM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ? Insider Monkey +6.32%
Dec-03-19 06:15AM  Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe Business Wire
Dec-02-19 04:56AM  Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares? Simply Wall St.
Nov-27-19 09:45AM  5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace
Nov-26-19 06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 06:30AM  Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% Business Wire
Nov-19-19 10:58AM  Aerie buys Spanish outfit as it moves toward profitability American City Business Journals
09:31AM  Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 06:30AM  Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program Business Wire
Nov-12-19 07:30AM  Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference Business Wire
05:41AM  Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 10:51AM  Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks -22.42%
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Nov-06-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Nov-05-19 06:30AM  Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan Business Wire
Oct-30-19 07:30AM  Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019 Business Wire
06:30AM  Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer Business Wire
Oct-29-19 10:33AM  Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 06:13PM  Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ? Insider Monkey +5.44%
Oct-25-19 06:40AM  Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62% Simply Wall St.
Oct-24-19 06:30AM  Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule Business Wire
Oct-16-19 07:15PM  Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer Business Wire
Sep-25-19 07:30AM  Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-23-19 01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
Sep-20-19 06:30AM  Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union Business Wire
Sep-19-19 07:39AM  The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga +5.87%
06:37AM  Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money? Simply Wall St.
06:30AM  Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility Business Wire
Sep-16-19 11:46AM  Weekly CEO Buys Highlight GuruFocus.com +7.92%
Sep-10-19 09:36PM  Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aeries 1.50% Convertible Senior Notes Due 2024 Business Wire +8.26%
Sep-09-19 07:15PM  Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Bought $499,012 of Shares GuruFocus.com +8.77%
06:00AM  These 2 Biotech Stocks Are Seeing Insider Buying Activity TheStreet.com
Sep-06-19 02:42PM  Durham pharma embarks on $275M financial trade American City Business Journals
09:31AM  Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-05-19 08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 08:20PM  Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024 Business Wire -9.31%
Sep-03-19 04:01PM  Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024 Business Wire -5.82%
Aug-26-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs Business Wire
Aug-20-19 06:30AM  Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Business Wire -5.78%
Aug-19-19 01:56PM  Zuckerberg Sells Shares of Facebook GuruFocus.com
Aug-08-19 04:08PM  This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily +6.65%
09:25AM  Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance Zacks
09:02AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
01:50AM  Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Jul-31-19 10:36AM  Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-19 09:23PM  Analysts Recommend Buying These 2 Falling Knives GuruFocus.com
Jul-25-19 07:30AM  Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire
Jul-18-19 06:26PM  Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks
08:22AM  Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals
Jul-11-19 06:46AM  How a Durham firm stands to benefit from an unexpected break in a Japanese trial American City Business Journals
Jul-09-19 05:48PM  Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks
06:30AM  Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule Business Wire
Jun-24-19 08:50AM  Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks
Jun-20-19 07:09PM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy? Insider Monkey
Jun-17-19 09:47PM  Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
06:30AM  Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting Business Wire
Jun-11-19 07:30AM  Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Jun-06-19 01:58PM  Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? Simply Wall St. -6.09%
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDBERG MURRAY ADirectorMay 18Option Exercise3.1528,00088,20036,050May 20 06:45 PM
Cagle Gerald D.DirectorMay 08Sale15.275,00076,35016,550May 12 05:25 PM
Foresite Capital Management II10% OwnerFeb 27Sale17.071,000,00017,070,0001,229,633Mar 02 05:01 PM
Kopczynski Casey C.Chief Scientific OfficerDec 03Option Exercise0.41117,00047,385218,511Dec 05 04:06 PM
RUBINO RICHARD JChief Financial OfficerSep 09Buy19.935,040100,447339,446Sep 09 05:45 PM
ANIDO VICENTE JRChief Executive OfficerSep 09Buy19.0126,250498,953197,631Sep 09 05:43 PM
Foresite Capital Management II10% OwnerSep 05Buy18.4215,700289,1942,350,477Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 04Buy18.48100,2001,851,6962,334,777Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 03Buy20.8150,0001,040,7412,325,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 30Buy21.3625,000534,0002,275,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 23Buy23.4238,300896,9862,250,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 22Buy23.686,700158,6562,212,177Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 21Buy23.251,15326,8072,205,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 20Buy23.2150,0001,160,5002,204,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 19Buy23.343,84789,7892,154,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 16Buy24.23100,0002,423,0002,150,477Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 14Buy23.73100,0002,373,0002,050,477Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 13Buy25.35250,0006,337,3421,310,000Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 12Buy24.43189,5554,630,8291,060,000Aug 14 08:15 PM